News

AmMax to participate in Cowen Conference on March 3rd. Read More>

AmMax Bio, Inc.

Slogan 2020 AmMax white 3 lines.png
shutterstock_1174276207_edited_edited.jp
shutterstock_1174276207_edited_edited.jp

AmMax Bio, Inc.

 
shutterstock_724957504_edited.jpg

ABOUT US​

Launched in March 2020 out of a partnership between LifeMax and Amgen, AmMax Bio, Inc. (“AmMax”) is a privately held, clinical stage biotech company focused on unlocking the therapeutic potential of the CSF1R platform (“colony stimulating factor 1 receptor”) to address diseases with significant unmet medical needs and sizable market potential. We have two clinical stage programs ready to enter Phase 2 studies.

November  18, 2022
AmMax Bio Announces Oral Presentation of Phase 2 Data of AMB-05X...

REDWOOD CITY, Calif. Nov 18, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including-...

September 26, 2022
AmMax Bio Provides Update on AMB-05X Program for Tenosynovial...

REDWOOD CITY, Calif. Sep. 26, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology including...

September 12, 2022
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of...

REDWOOD CITY, Calif. March  2, 2022 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including...

NEWS

shutterstock_1682600770_edited.jpg

R&D

AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis, retinal disease (nAMD/DME) and polycystic kidney diseases, by leveraging the action of AMB-05X on inflammation, fibrosis and neovascularization.

Slogan 2020 AmMax white 3 lines.png

News

AmMax Bio Announces Presentation of AMB-05X for TGCT at 2022 CTOS...
Read More>